A Ubiquinone-Reactive Pt(IV) Prodrug Perturbs Mitochondrial Metabolism for Selective Tumor Suppression
ACS Applied Bio Materials · 2026
DOI: 10.1021/acsabm.6c01398 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Bio Materials, 2026. Verfasst von Yi Dai und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Science, Anhui Xinhua University, Hefei230088, China. Hauptthemen laut MEDLINE: Prodrugs, Mitochondria, Antineoplastic Agents, Ubiquinone. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Key Project of Natural Science Research, Anhui Xinhua University, USTC Research Funds of the Double First-Class Initiative, Anhui Provincial Clinical Medicine Research and Transformation Special Project.
Abstract (Originalsprache)
Pt(IV) prodrugs offer a versatile platform for the design of platinum-based antitumor drugs; yet utilizing axial ligands to actively modulate tumor bioenergetics has been less investigated. Herein, we report a mitochondria-directed Pt(IV) prodrug, LA-Pt(IV), in which lipoic acid (LA) serves as a metabolite-reactive axial ligand enabling selective tumor suppression. Upon cellular internalization, LA-Pt(IV) preferentially accumulates in the mitochondria and undergoes intracellular reduction to release cytotoxic Pt(II) species together with lipoic acid-derived dihydrolipoic acid (DHLA). While the Pt(II) species induce DNA damage, DHLA undergoes the Michael addition reaction with endogenous ubiquinone (UQ), thereby depleting this key electron carrier and disrupting mitochondrial electron transport. This process triggers profound mitochondrial dysfunction, bioenergetic collapse, and a lethal burst of reactive oxygen species (ROS). Notably, LA-Pt(IV) exhibits markedly enhanced potency and selectivity toward multiple cancer cell lines relative to cisplatin. In vivo studies confirmed that LA-Pt(IV) achieves potent tumor inhibition with substantially reduced systemic toxicity. This work establishes a dual-targeting strategy for platinum drug design by incorporating the reactive ligand to perturb endogenous metabolism associated with mitochondrial electron transport.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmaceutical Science, Anhui Xinhua University, Hefei230088, China.
- Department of Pharmacy, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, Key Laboratory of Precision and Intelligent Chemistry, School of Chemistry and Materials Science, University of Scie…
ORCID-Profile: Yichen Yin, Zhaolin Chen, Yangzhong Liu
Förderung
- Key Project of Natural Science Research, Anhui Xinhua University
- USTC Research Funds of the Double First-Class Initiative
- Anhui Provincial Clinical Medicine Research and Transformation Special Project
- Plans for Major Provincial Science & Technology Projects
- Key Natural Science Project of University Research Program of Anhui Province
- Key R&D Project of the China National Tobacco Corporation
- College Outstanding Youth Talents Fund Project of Anhui Province
- National Natural Science Foundation of China (NSFC)
Zitieren
APA
Dai, Y., Yu, W., Yin, Y., Chen, F., Zheng, J., Chen, Z., Zhang, L., & Liu, Y. (2026). A Ubiquinone-Reactive Pt(IV) Prodrug Perturbs Mitochondrial Metabolism for Selective Tumor Suppression. ACS Applied Bio Materials. https://doi.org/10.1021/acsabm.6c01398
Vancouver
Dai Y, Yu W, Yin Y, Chen F, Zheng J, Chen Z, et al. A Ubiquinone-Reactive Pt(IV) Prodrug Perturbs Mitochondrial Metabolism for Selective Tumor Suppression. ACS Applied Bio Materials. 2026. doi:10.1021/acsabm.6c01398
BibTeX
@article{Dai2026,
author = {Dai, Yi and Yu, Wenxin and Yin, Yichen and Chen, Fei and Zheng, Jingyun and Chen, Zhaolin and Zhang, Lei and Liu, Yangzhong},
title = {A Ubiquinone-Reactive Pt(IV) Prodrug Perturbs Mitochondrial Metabolism for Selective Tumor Suppression},
journal = {ACS Applied Bio Materials},
year = {2026},
doi = {10.1021/acsabm.6c01398}
}
EUVIMED